(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 5.31% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.57%.
Gilead Sciences's revenue in 2026 is $29,736,000,000.On average, 32 Wall Street analysts forecast GILD's revenue for 2026 to be $38,518,463,770,976, with the lowest GILD revenue forecast at $36,282,396,427,902, and the highest GILD revenue forecast at $40,152,369,725,160. On average, 31 Wall Street analysts forecast GILD's revenue for 2027 to be $40,913,452,057,922, with the lowest GILD revenue forecast at $37,788,420,685,064, and the highest GILD revenue forecast at $43,887,011,906,152.
In 2028, GILD is forecast to generate $43,077,508,348,304 in revenue, with the lowest revenue forecast at $39,496,820,831,688 and the highest revenue forecast at $49,383,441,738,350.